Novo Nordisk CEO Lars Fruergaard Jørgensen faced Senate scrutiny over the high prices of Wegovy and Ozempic as U.S. demand surges. While Jørgensen did not commit to lowering prices, he was willing to work on policy solutions to reduce prescription drug costs. Sen. Bernie Sanders urged Novo Nordisk CEO Lars Fruergaard Jørgensen to reduce the high U.S. prices of Wegovy and Ozempic, stating, “Stop ripping us off” and calling for equal treatment for Americans. Lawmakers continue to pressure the pharmaceutical industry to cut prices amid growing healthcare costs.
Category
🗞
NewsTranscript
00:00It's Benzinga, and here's what's on the block.
00:02Novo Nordisk CEO Lars Fruehrigard Jørgensen faced Senate scrutiny over the high prices
00:07of WeGovie and Ozempic as U.S. demand surges.
00:11While Jørgensen did not commit to lowering prices, he expressed a willingness to work
00:15on policy solutions to reduce prescription drug costs.
00:18Senator Bernie Sanders urged Novo Nordisk CEO Lars Fruehrigard Jørgensen to reduce
00:23the high U.S. prices of WeGovie and Ozempic, stating,
00:26And stop ripping us off and calling for equal treatment for Americans.
00:30Lawmakers continue to pressure the pharmaceutical industry to cut prices amid growing health
00:34care costs.
00:35For all things money, visit Benzinga.com.